Annual FCF
-$246.00 M
-$2.20 M-0.90%
31 December 2023
Summary:
Sangamo Therapeutics annual free cash flow is currently -$246.00 million, with the most recent change of -$2.20 million (-0.90%) on 31 December 2023. During the last 3 years, it has fallen by -$401.16 million (-258.54%). SGMO annual FCF is now -258.54% below its all-time high of $155.16 million, reached on 31 December 2020.SGMO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$11.64 M
+$38.53 M+143.31%
30 September 2024
Summary:
Sangamo Therapeutics quarterly free cash flow is currently $11.64 million, with the most recent change of +$38.53 million (+143.31%) on 30 September 2024. Over the past year, it has increased by +$61.68 million (+123.27%). SGMO quarterly FCF is now -92.59% below its all-time high of $157.07 million, reached on 30 June 2020.SGMO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$117.11 M
+$61.68 M+34.50%
30 September 2024
Summary:
Sangamo Therapeutics TTM free cash flow is currently -$117.11 million, with the most recent change of +$61.68 million (+34.50%) on 30 September 2024. Over the past year, it has increased by +$140.20 million (+54.49%). SGMO TTM FCF is now -175.48% below its all-time high of $155.16 million, reached on 31 December 2020.SGMO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.9% | +123.3% | +54.5% |
| 3 y3 years | -258.5% | +118.0% | +44.0% |
| 5 y5 years | -3675.9% | +127.1% | +43.1% |
SGMO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -258.5% | +4.1% | at high | +115.2% | at high | +55.9% |
| 5 y | 5 years | -258.5% | +4.1% | -92.6% | +115.2% | -175.5% | +55.9% |
| alltime | all time | -258.5% | +4.1% | -92.6% | +115.2% | -175.5% | +55.9% |
Sangamo Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $11.64 M(-143.3%) | -$117.11 M(-34.5%) |
| June 2024 | - | -$26.88 M(-44.8%) | -$178.79 M(-18.0%) |
| Mar 2024 | - | -$48.66 M(-8.5%) | -$218.16 M(-11.3%) |
| Dec 2023 | -$246.00 M(+0.9%) | -$53.21 M(+6.3%) | -$246.00 M(-4.4%) |
| Sept 2023 | - | -$50.04 M(-24.5%) | -$257.31 M(-3.0%) |
| June 2023 | - | -$66.25 M(-13.4%) | -$265.31 M(+2.6%) |
| Mar 2023 | - | -$76.50 M(+18.6%) | -$258.48 M(+6.0%) |
| Dec 2022 | -$243.80 M(-5.0%) | -$64.52 M(+11.2%) | -$243.80 M(+3.8%) |
| Sept 2022 | - | -$58.03 M(-2.4%) | -$234.85 M(-2.7%) |
| June 2022 | - | -$59.43 M(-3.9%) | -$241.44 M(-0.2%) |
| Mar 2022 | - | -$61.81 M(+11.2%) | -$241.84 M(-5.7%) |
| Dec 2021 | -$256.53 M(-265.3%) | -$55.57 M(-14.0%) | -$256.53 M(+22.6%) |
| Sept 2021 | - | -$64.63 M(+8.0%) | -$209.26 M(+81.1%) |
| June 2021 | - | -$59.83 M(-21.8%) | -$115.58 M(-214.1%) |
| Mar 2021 | - | -$76.50 M(+821.0%) | $101.33 M(-34.7%) |
| Dec 2020 | $155.16 M(-194.0%) | -$8.31 M(-128.6%) | $155.16 M(+14.2%) |
| Sept 2020 | - | $29.06 M(-81.5%) | $135.87 M(+112.9%) |
| June 2020 | - | $157.07 M(-793.0%) | $63.80 M(-146.7%) |
| Mar 2020 | - | -$22.66 M(-17.9%) | -$136.65 M(-17.2%) |
| Dec 2019 | -$165.08 M(+2433.8%) | -$27.60 M(-35.8%) | -$165.08 M(-19.7%) |
| Sept 2019 | - | -$43.01 M(-0.8%) | -$205.68 M(+3.1%) |
| June 2019 | - | -$43.38 M(-15.1%) | -$199.53 M(+441.3%) |
| Mar 2019 | - | -$51.10 M(-25.1%) | -$36.86 M(+465.8%) |
| Dec 2018 | -$6.51 M(-187.7%) | -$68.20 M(+85.0%) | -$6.51 M(-114.8%) |
| Sept 2018 | - | -$36.86 M(-130.9%) | $43.96 M(-31.8%) |
| June 2018 | - | $119.29 M(-674.9%) | $64.43 M(>+9900.0%) |
| Mar 2018 | - | -$20.75 M(+17.1%) | $224.00 K(-97.0%) |
| Dec 2017 | $7.43 M(-111.2%) | -$17.72 M(+8.1%) | $7.43 M(-43.5%) |
| Sept 2017 | - | -$16.39 M(-129.7%) | $13.16 M(+11.4%) |
| June 2017 | - | $55.08 M(-506.6%) | $11.81 M(-119.8%) |
| Mar 2017 | - | -$13.55 M(+13.0%) | -$59.55 M(-10.6%) |
| Dec 2016 | -$66.61 M(+97.6%) | -$11.99 M(-32.4%) | -$66.61 M(+8.5%) |
| Sept 2016 | - | -$17.73 M(+8.9%) | -$61.40 M(+5.7%) |
| June 2016 | - | -$16.28 M(-21.0%) | -$58.11 M(+14.3%) |
| Mar 2016 | - | -$20.61 M(+204.1%) | -$50.85 M(+50.8%) |
| Dec 2015 | -$33.72 M(+494.2%) | -$6.78 M(-53.1%) | -$33.72 M(+15.9%) |
| Sept 2015 | - | -$14.44 M(+60.1%) | -$29.10 M(+41.8%) |
| June 2015 | - | -$9.02 M(+159.5%) | -$20.52 M(+0.5%) |
| Mar 2015 | - | -$3.48 M(+61.5%) | -$20.41 M(+259.6%) |
| Dec 2014 | -$5.67 M(-71.5%) | -$2.15 M(-63.3%) | -$5.67 M(+8.8%) |
| Sept 2014 | - | -$5.86 M(-34.2%) | -$5.22 M(+33.3%) |
| June 2014 | - | -$8.91 M(-179.2%) | -$3.91 M(+580.7%) |
| Mar 2014 | - | $11.25 M(-764.3%) | -$575.00 K(-97.1%) |
| Dec 2013 | -$19.91 M(+126.2%) | -$1.69 M(-62.9%) | -$19.91 M(+8.5%) |
| Sept 2013 | - | -$4.56 M(-18.2%) | -$18.36 M(-3.7%) |
| June 2013 | - | -$5.57 M(-31.1%) | -$19.06 M(-2.5%) |
| Mar 2013 | - | -$8.09 M(+5802.2%) | -$19.54 M(+121.9%) |
| Dec 2012 | -$8.80 M | -$137.00 K(-97.4%) | -$8.80 M(-0.7%) |
| Sept 2012 | - | -$5.26 M(-13.2%) | -$8.87 M(-13.5%) |
| June 2012 | - | -$6.06 M(-328.7%) | -$10.26 M(-12.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $2.65 M(-1404.9%) | -$11.75 M(-55.6%) |
| Dec 2011 | -$26.47 M(+7.5%) | -$203.00 K(-96.9%) | -$26.47 M(-8.4%) |
| Sept 2011 | - | -$6.64 M(-12.1%) | -$28.90 M(+2.2%) |
| June 2011 | - | -$7.56 M(-37.4%) | -$28.27 M(-0.3%) |
| Mar 2011 | - | -$12.07 M(+358.5%) | -$28.35 M(+15.1%) |
| Dec 2010 | -$24.63 M(+284.3%) | -$2.63 M(-56.3%) | -$24.63 M(+134.4%) |
| Sept 2010 | - | -$6.02 M(-21.2%) | -$10.51 M(+15.0%) |
| June 2010 | - | -$7.64 M(-8.5%) | -$9.13 M(+19.5%) |
| Mar 2010 | - | -$8.34 M(-172.6%) | -$7.64 M(+19.3%) |
| Dec 2009 | -$6.41 M(-64.6%) | $11.49 M(-347.3%) | -$6.41 M(-47.7%) |
| Sept 2009 | - | -$4.65 M(-24.4%) | -$12.24 M(-3.1%) |
| June 2009 | - | -$6.14 M(-13.6%) | -$12.64 M(-23.1%) |
| Mar 2009 | - | -$7.11 M(-225.7%) | -$16.44 M(-9.1%) |
| Dec 2008 | -$18.08 M(+3.7%) | $5.66 M(-212.2%) | -$18.08 M(-38.5%) |
| Sept 2008 | - | -$5.04 M(-49.3%) | -$29.39 M(+16.9%) |
| June 2008 | - | -$9.95 M(+13.6%) | -$25.15 M(+21.5%) |
| Mar 2008 | - | -$8.75 M(+54.8%) | -$20.70 M(+18.7%) |
| Dec 2007 | -$17.44 M(+17.4%) | -$5.66 M(+609.5%) | -$17.44 M(+11.1%) |
| Sept 2007 | - | -$797.00 K(-85.5%) | -$15.69 M(-10.2%) |
| June 2007 | - | -$5.50 M(+0.2%) | -$17.47 M(+10.3%) |
| Mar 2007 | - | -$5.49 M(+40.5%) | -$15.84 M(+6.6%) |
| Dec 2006 | -$14.85 M(+230.3%) | -$3.91 M(+51.4%) | -$14.85 M(+162.4%) |
| Sept 2006 | - | -$2.58 M(-33.2%) | -$5.66 M(+6.0%) |
| June 2006 | - | -$3.86 M(-14.2%) | -$5.34 M(-4.5%) |
| Mar 2006 | - | -$4.50 M(-185.2%) | -$5.59 M(+24.3%) |
| Dec 2005 | -$4.50 M(-55.9%) | $5.29 M(-334.0%) | -$4.50 M(-61.1%) |
| Sept 2005 | - | -$2.26 M(-45.1%) | -$11.57 M(-7.9%) |
| June 2005 | - | -$4.12 M(+20.7%) | -$12.56 M(+9.5%) |
| Mar 2005 | - | -$3.41 M(+91.0%) | -$11.47 M(+12.6%) |
| Dec 2004 | -$10.19 M(+35.8%) | -$1.78 M(-45.1%) | -$10.19 M(+0.8%) |
| Sept 2004 | - | -$3.25 M(+7.3%) | -$10.11 M(+33.6%) |
| June 2004 | - | -$3.03 M(+42.7%) | -$7.56 M(+11.1%) |
| Mar 2004 | - | -$2.12 M(+24.7%) | -$6.81 M(-9.3%) |
| Dec 2003 | -$7.50 M(-16.1%) | -$1.70 M(+141.2%) | -$7.50 M(+49.9%) |
| Sept 2003 | - | -$706.00 K(-69.0%) | -$5.00 M(-31.0%) |
| June 2003 | - | -$2.28 M(-19.3%) | -$7.25 M(-21.1%) |
| Mar 2003 | - | -$2.82 M(-454.1%) | -$9.20 M(+2.9%) |
| Dec 2002 | -$8.95 M(+19.1%) | $796.00 K(-126.9%) | -$8.95 M(-16.8%) |
| Sept 2002 | - | -$2.96 M(-30.0%) | -$10.76 M(+10.3%) |
| June 2002 | - | -$4.22 M(+64.6%) | -$9.76 M(+7.2%) |
| Mar 2002 | - | -$2.56 M(+152.4%) | -$9.10 M(+21.2%) |
| Dec 2001 | -$7.51 M(+78.6%) | -$1.02 M(-48.0%) | -$7.51 M(+5.1%) |
| Sept 2001 | - | -$1.96 M(-45.2%) | -$7.14 M(+13.4%) |
| June 2001 | - | -$3.57 M(+267.5%) | -$6.30 M(+20.1%) |
| Mar 2001 | - | -$971.00 K(+49.2%) | -$5.25 M(+24.8%) |
| Dec 2000 | -$4.20 M(+55.7%) | -$651.00 K(-41.3%) | -$4.20 M(+18.3%) |
| Sept 2000 | - | -$1.11 M(-55.9%) | -$3.55 M(+45.4%) |
| June 2000 | - | -$2.51 M(-3691.4%) | -$2.44 M(-3591.4%) |
| Mar 2000 | - | $70.00 K | $70.00 K |
| Dec 1999 | -$2.70 M | - | - |
FAQ
- What is Sangamo Therapeutics annual free cash flow?
- What is the all time high annual FCF for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual FCF year-on-year change?
- What is Sangamo Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly FCF year-on-year change?
- What is Sangamo Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM FCF year-on-year change?
What is Sangamo Therapeutics annual free cash flow?
The current annual FCF of SGMO is -$246.00 M
What is the all time high annual FCF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual free cash flow is $155.16 M
What is Sangamo Therapeutics annual FCF year-on-year change?
Over the past year, SGMO annual free cash flow has changed by -$2.20 M (-0.90%)
What is Sangamo Therapeutics quarterly free cash flow?
The current quarterly FCF of SGMO is $11.64 M
What is the all time high quarterly FCF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly free cash flow is $157.07 M
What is Sangamo Therapeutics quarterly FCF year-on-year change?
Over the past year, SGMO quarterly free cash flow has changed by +$61.68 M (+123.27%)
What is Sangamo Therapeutics TTM free cash flow?
The current TTM FCF of SGMO is -$117.11 M
What is the all time high TTM FCF for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM free cash flow is $155.16 M
What is Sangamo Therapeutics TTM FCF year-on-year change?
Over the past year, SGMO TTM free cash flow has changed by +$140.20 M (+54.49%)